See more : Escape Hunt plc (ESC.L) Income Statement Analysis – Financial Results
Complete financial analysis of ProtoKinetix, Incorporated (PKTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProtoKinetix, Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Arafura Rare Earths Limited (ARU.AX) Income Statement Analysis – Financial Results
- Groupe Open (OPN.PA) Income Statement Analysis – Financial Results
- Oxford Lane Capital Corp. (OXLC) Income Statement Analysis – Financial Results
- Fondia Oyj (FONDIA.HE) Income Statement Analysis – Financial Results
- NIO Inc. (N3IA.F) Income Statement Analysis – Financial Results
ProtoKinetix, Incorporated (PKTX)
About ProtoKinetix, Incorporated
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 124.00 | 0.00 |
| Cost of Revenue | 48.26K | 58.45K | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 1.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -48.26K | -58.45K | -3.00K | -3.00K | -3.00K | -3.00K | -3.00K | -3.00K | -1.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K | 0.00 | 0.00 | 0.00 | 124.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% |
| Research & Development | 112.44K | 448.87K | 435.87K | 527.29K | 369.52K | 337.07K | 296.52K | 450.90K | 158.89K | 13.75K | 74.50K | 0.00 | 117.42K | 161.51K | 175.96K | 405.28K | 996.54K | 180.71K | 410.65K | 209.53K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 254.78K | 1.40M | 1.89M | 7.11M | 3.83M | 875.97K | 1.21M | 1.07M | 1.10M | 370.43K | 347.68K | 173.12K | 787.52K | 1.21M | 1.07M | 1.12M | 1.72M | 0.00 | 0.00 | 5.16M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 254.78K | 1.40M | 1.89M | 7.11M | 3.83M | 875.97K | 1.21M | 1.07M | 1.10M | 370.43K | 347.68K | 173.12K | 787.52K | 1.21M | 1.07M | 1.12M | 1.72M | 1.78M | 4.40M | 5.16M | 1.52M | 14.88K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 58.45K | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 1.50K | 228.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.03K | 35.00 |
| Operating Expenses | 415.48K | 1.91M | 2.33M | 7.64M | 4.20M | 1.22M | 1.51M | 1.52M | 1.26M | 384.18K | 422.18K | 173.12K | 904.93K | 1.37M | 1.25M | 1.55M | 2.72M | 1.96M | 4.82M | 5.37M | 1.52M | 14.88K | 17.03K | 35.00 |
| Cost & Expenses | 415.48K | 1.91M | 2.33M | 7.64M | 4.20M | 1.22M | 1.51M | 1.52M | 1.26M | 384.18K | 422.18K | 173.12K | 904.93K | 1.37M | 1.25M | 1.55M | 2.72M | 1.96M | 4.82M | 5.37M | 1.52M | 14.88K | 17.03K | 35.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 306.00 | 1.66K | 12.00 | 3.97K | 34.42K | 26.40K | 24.00K | 12.00K | 24.00K | 24.00K | 24.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 48.26K | 58.45K | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 3.00K | 1.50K | 384.18K | 422.18K | 173.12 | -315.00K | 8.64K | 0.00 | 426.00 | 1.02K | 1.02K | 674.00 | 253.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -367.22K | -1.85M | -2.33M | -7.64M | -4.19M | -1.21M | -1.51M | -1.52M | -1.26M | 215.70K | -26.40K | -173.12K | -1.22M | -1.36M | -1.25M | -1.53M | -2.72M | -1.95M | -4.81M | -5.36M | -1.52M | -14.88K | -16.90K | -35.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -227,145.85% | 0.00% | 0.00% | 0.00% | -13,630.65% | 0.00% |
| Operating Income | -415.48K | -1.91M | -2.33M | -7.64M | -4.20M | -1.22M | -1.51M | -1.52M | -1.26M | -384.18K | -422.18K | -173.12K | -904.93K | -1.37M | -1.25M | -1.55M | -2.72M | -1.96M | -4.81M | -5.37M | -1.52M | -14.88K | -16.90K | -35.00 |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -240,667.35% | 0.00% | 0.00% | 0.00% | -13,630.65% | 0.00% |
| Total Other Income/Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -1.00 | -306.00 | -1.66K | -12.00 | 3.30K | 215.70K | -26.40K | -24.00K | 315.00K | -8.64K | 0.00 | 0.00 | -12.00K | -11.87K | -13.19K | -23.10K | 0.00 | 0.00 | 16.90K | 0.00 |
| Income Before Tax | -415.48K | -1.91M | -2.33M | -7.64M | -4.20M | -1.22M | -1.51M | -1.52M | -1.25M | -168.48K | -448.58K | -197.12K | -589.93K | -1.38M | 0.00 | 0.00 | 0.00 | 0.00 | -5.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254,155.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.00 | -233.56K | -203.30K | 1.00 | -158.14K | 0.00 | 0.00 | -3.30K | -349.76K | -422.18K | -173.12 | 642.00K | 6.72K | 1.27M | 0.00 | 12.00K | 11.87K | 282.95K | 23.10K | 1.53M | 14.88K | 16.90K | 35.00 |
| Net Income | -415.48K | -1.91M | -2.33M | -7.64M | -4.20M | -1.22M | -1.51M | -1.52M | -1.25M | -168.48K | -448.58K | -197.12K | -1.23M | -1.39M | -1.27M | -1.55M | -2.73M | -1.97M | -5.10M | -5.39M | -1.53M | -14.88K | -16.90K | -35.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254,814.80% | 0.00% | 0.00% | 0.00% | -13,630.65% | 0.00% |
| EPS | -0.01 | -0.01 | -0.01 | -0.03 | -0.02 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 | -0.03 | -0.06 | -0.05 | -0.13 | -0.18 | -0.09 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.03 | -0.02 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.02 | -0.03 | -0.06 | -0.05 | -0.13 | -0.18 | -0.09 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 41.55M | 307.39M | 291.87M | 278.60M | 268.98M | 256.22M | 246.60M | 237.95M | 216.60M | 175.66M | 137.11M | 129.22M | 93.59M | 75.47M | 60.82M | 57.08M | 45.75M | 43.23M | 38.60M | 29.94M | 17.15M | 15.09M | 6.04M | 216.99M |
| Weighted Avg Shares Out (Dil) | 333.10M | 307.39M | 291.87M | 278.60M | 268.98M | 256.22M | 246.60M | 237.95M | 216.60M | 175.66M | 137.11M | 129.22M | 93.59M | 75.47M | 60.82M | 57.08M | 45.75M | 43.23M | 38.60M | 29.94M | 17.15M | 15.09M | 6.04M | 216.99M |
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
MARIETTA, Ohio--(BUSINESS WIRE)---- $PKTX #AMD--ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions
Source: https://incomestatements.info
Category: Stock Reports